The pharmaceutical field has always churned out new compounds in the endless hunt for better therapies. N-Benzyl Paroxetine Hydrochloride stems from decades of serendipity, trial, and the growing understanding of chemical engineering layered onto psychopharmacology innovation. Labs searching for more selective serotonin reuptake inhibitors found fertile ground by making small tweaks on structural frameworks. Researchers saw patterns: changing side chains or functional groups sometimes unlocked stronger or more focused receptor activity. N-Benzyl Paroxetine Hydrochloride follows this path. Chemists started with paroxetine, a familiar SSRI, but wanted to see if adding a benzyl group to the nitrogen atom would nudge its pharmacological fingerprint a notch higher. By the late 2000s, a few teams had documented improved selectivity or utility in certain analytic routes, and a range of chemical suppliers picked up custom synthesis. People working behind the glassware paid close attention as this modification revealed new answers, as well as fresh questions about the nuanced dance between molecular structure and biological effect.
Looking at N-Benzyl Paroxetine Hydrochloride, the term itself points to the fundamental scaffold: a classic paroxetine backbone with an N-benzyl attachment, delivered as a hydrochloride salt. To most chemists and some clinicians, the real story sits in the hue of the powder and purity levels. Common preparations yield an off-white solid, crystalline and tightly packed into containers shielded from moisture. Handling this material feels familiar, at least to anyone used to working around common SSRIs or their analogs, though the benzyl group adds enough bulk to slightly alter everything from solubility to its flavor in bench chemistry. Raw or finished, most of the substance flows on the back of bespoke demand, with the pharmaceutical world watching for updates in application. A big draw comes from how new analogs like this help open doors in medicinal chemistry, even if only a handful make it beyond the research shelves.
Anyone peering in for the physical details meets a solid, fine-grained powder, generally off-white and not particularly smelly. Most batches clock a melting point somewhere between 154°C to 160°C, revealing a structure that's both thermally robust and suitable for further manipulation at the lab bench. Solubility tells a richer tale. The hydrochloride salt dissolves nicely in aqueous solutions and polar solvents. It turns cloudy or stays suspended in low-polarity, organic mixtures. Chemists lean on specific gravity, refractive index, and sometimes a very particular type of crystallinity, depending on their downstream needs. The paroxetine core brings plenty of legacy data, and N-Benzyl modification means teams must still run checks for any new hazard profiles or handling quirks. Keeping a dry, well-sealed storage environment matters, mainly to prevent clumping or minor degradation from ambient humidity.
Suppliers catalog N-Benzyl Paroxetine Hydrochloride under varying purity percentages, though 98% and higher remains the gold standard. Certificates typically include identification using HPLC, NMR, and IR to verify the molecular fingerprint. Moisture content, heavy metals, residue on ignition, and chromatographic purity matter when people go from research-bench to pilot scale. Accurate labeling should list lot numbers, manufacturing date, and MSDS-compliant hazard information—chemical safety cycles move quickly, and clear paperwork helps everyone avoid missteps if vials turn up in old storage. Precise molecular weight, molecular formula, CAS number, and batch purity play a central role in compliance, especially in jurisdictions demanding traceability. Honest reporting, even about minor contaminants, keeps everyone safer in both research and industrial use. It never pays to cut corners with paperwork or documentation.
Making N-Benzyl Paroxetine Hydrochloride calls for some patience and a lot of caution. Start with paroxetine as your base. The decisive moment comes during the N-benzylation step, usually through reaction with benzyl chloride in the presence of an organic or inorganic base such as sodium hydride. Careful solvent selection—often dimethylformamide—prevents side reactions, while controlling temperature fends off over-alkylation or weird byproducts. After reaction, the free base must be isolated and converted swiftly to the hydrochloride salt using HCl gas or solution. Each step brings its own headaches: incomplete benzylation causes purification issues; mild overheating degrades yield. Special emphasis lands on stripping away solvents and neutralizing any remaining reagents before drying the compound. In a commercial setting, scale-up amplifies every tiny inefficiency or risk, so process engineers invest hours in optimizing each parameter before approving batches for any research or market use.
This molecule invites curiosity about further derivatization. Chemists attack the aromatic rings, position-selective oxidation or reduction, and the potential for coupling to fluorescent or affinity tags through the benzyl group. Modifications can tweak both the pharmacological profile and analytical capabilities. Sometimes, the N-benzyl position accommodates heavier functional groups, promising new activity in preclinical screens. Reactivity under mild acid or base helps sort out stability, offering clues for shelf life. Some lines of research use the hydrochloride salt as a midpoint—strip off the benzyl group and gauge biological activity, or swap in other aryl or alkyl fragments. This kind of tinkering keeps the molecule on radar for labs interested in targeted therapeutics or as building blocks for more specialized compounds.
Catalogs and chemical search engines toss back a few alternative handles. N-Benzyl Paroxetine Hydrochloride sometimes surfaces as Benzylparoxetine HCl or Paroxetine N-Benzyl Hydrochloride for quick reference. Cheminformatics giants assign standardized registry numbers and include this under broader SSRI analog umbrellas. As with many niche molecules, not every supplier or research paper sticks to the same shorthand, so double-checking product numbers, registry codes, and supplier specs saves wasted time and effort. Labs that use synonyms with clarity give a better experience for newcomers trying to untangle procurement or documentation.
Both experienced chemists and new hires should start by reading the MSDS carefully. N-Benzyl Paroxetine Hydrochloride shares some class hazards with traditional paroxetine: possible skin and eye irritancy, risks if inhaled or accidentally ingested, and uncertain chronic effects without full toxicity profiles. Many workplaces treat the compound as a “handling with gloves and goggles” scenario. Fume hoods and careful weighing become routine. Cleanroom or GMP-accredited synthesis ramps up quality control and contamination checks, with regular spot checks for air and workspace purity. Storage adopts the same rigor—sealed in amber glass away from light and humidity, with access logs for regulatory trace-back. Teams emphasize spill protocols and rapid clean-up, since nobody wants even a microgram lingering in a shared workspace. Training goes beyond the basics, covering emergency eye-wash, first aid, and waste disposal in line with local and international regulations.
Most interest in N-Benzyl Paroxetine Hydrochloride runs through research circuits: medicinal chemistry, molecular probes, and sometimes exploratory neuropharmacology. The analog’s unique structure allows it to act as a template for receptor binding studies or as a control in experiments teasing out subtle differences within the vast family of SSRIs. Some forensic and analytical labs use the compound as an internal standard or marker when validating high-throughput detection screens. Startups and CROs sometimes field test novel SSRIs with tweaks like N-Benzylation to sift for better side-effect profiles. Beyond bench research, large-scale clinical trials remain rare; this molecule rests mostly in early-stage evaluations, far from market shelves seen by ordinary patients.
The research machine chugs forward, always hungry for distinct molecular frameworks to solve both clinical and scientific puzzles. Academic teams leverage N-Benzyl Paroxetine Hydrochloride to probe the serotonin transporter in both cell and animal models. This allows a comparison: does the new benzyl group enhance or impair receptor selectivity, metabolic stability, or blood-brain barrier penetration? Pharma companies sniff out leads for improved or distinct SSRIs, especially where slight structure changes mute common side effects. In my own experience, the real action often takes place in collaborative networks where chemists, pharmacologists, and toxicologists pass samples, share spectra, and open gaps for the next generation to explore. Each new result builds on months—sometimes years—of groundwork, and every published paper means a step closer to a possible therapy or a new tool for brain science.
Any experimenter working around psychoactive or biologically active compounds learns quickly not to assume class safety. Early toxicity checks move in phases. Animal models receive graded microdoses with researchers watching for both acute reactions and subtle behavioral changes. In vitro assays look for genotoxicity, interactions with cytochrome P450 enzymes, or hints of organ-specific effects. Most SSRIs present relatively safe profiles at low exposure, but even small structural modifications can create wildcards. Data from an N-Benzyl group may kick up unpredicted metabolic byproducts, which requires scrutiny before anyone considers larger trials. I’ve seen just how careful planning and detailed animal welfare oversight can spot red flags before real harm appears. Long-term outcomes remain unclear until the compound faces broad toxicokinetic profiling, so most reports urge caution and incremental review.
New analogs like N-Benzyl Paroxetine Hydrochloride signal the ever-evolving nature of pharmaceutical chemistry. Even if this exact molecule never breaks out as a blockbuster drug, every insight from its synthesis, analysis, and biological testing feeds into smarter drug design. As regulatory systems put higher standards on both lab safety and efficacy data, researchers will lean on robust methods of screening and rapid characterization—and N-Benzyl Paroxetine Hydrochloride will continue as both a benchmark and a branching point. The future suggests a world in which these kinds of modifications give birth to faster, safer, or more targeted therapies with far fewer side effects, as long as everyone keeps valuing rigorous data and sharing results. Chemical innovation rarely moves in a straight line; yesterday’s byproduct can turn into tomorrow’s foundation for a new family of brain-health therapies.
N-Benzyl Paroxetine Hydrochloride stands as a chemical compound closely related to paroxetine, which many recognize as an antidepressant from the SSRI family. This benzyl derivative attracts attention mainly in research and scientific studies, not in everyday pharmacy shelves. It does not show up in prescriptions for mood disorders like depression or anxiety, but its value in the scientific world runs deep.
Researchers often use N-Benzyl Paroxetine Hydrochloride to explore how drugs interact with the serotonin transporter in the brain. The original paroxetine molecule targets the serotonin system, which influences mood, emotion, and various cognitive functions. By tweaking the structure and adding a benzyl group, scientists can shape its activity and selectivity. This kind of chemical modification helps in building a foundation for testing next-generation antidepressants or brain-acting compounds before bringing them to clinical trials.
In the lab, chemical probes like this one help map the brain’s receptors or even aid in studying the metabolism of related pharmaceuticals. For anyone working in neuropharmacology or medicinal chemistry, knowing how molecules get in and out of key sites matters a lot. I remember talking with a neuroscientist at a conference who saw great promise in N-Benzyl Paroxetine derivatives for refining diagnostic imaging agents—a development that could one day support earlier detection of neurological disorders.
The use of N-Benzyl Paroxetine Hydrochloride remains strictly preclinical. Its structure makes it an ideal model for binding studies and for exploring the design of SSRIs with fewer side effects or sharper focus on certain neurotransmitter pathways. Research teams often start with molecules like this to run computer-aided drug design studies, then test a small batch in a controlled lab environment.
It’s not meant for self-experimentation or for treating patients, and there’s a legal and safety barrier for anyone outside a licensed laboratory. Accidental or unregulated handling of such compounds could have consequences, especially since these chemicals can be potent—affecting brain chemistry long before anyone can study their side effects in people.
The internet sometimes presents research chemicals as shortcuts or solutions for mental health struggles. This can lead to misuse or outright danger. Drugs that modulate serotonin levels interact with heart rhythms, emotional balance, and even digestion. No lab chemical, including N-Benzyl Paroxetine Hydrochloride, belongs outside a professional setting.
The scientific process depends on rigor and oversight. Just sourcing or using research chemicals informally skips critical testing phases—those that filter out toxic side effects and long-term health problems. Regulatory agencies work hard to prevent these substances from leaking into recreational use, and with good reason. Many of the world’s top SSRIs only reached the market after years of rigorous safety and efficacy studies.
Interest in N-Benzyl Paroxetine Hydrochloride shows there’s no shortage of curiosity in how our brains work and how drugs might improve mental health. The responsible path involves supporting research, protecting patient safety, and investing in the kind of medical science that treats root problems, not just symptoms. Exploring these molecules under the guidance of ethics boards and skilled chemists builds real hope for new therapies—ones grounded in evidence and safety, not shortcuts or speculation.
People ask about the recommended dosage for N-Benzyl Paroxetine Hydrochloride, hoping to find a clear answer. The truth can be a little sobering: at present, no reputable medical authority offers a standard dosage for this compound, because it does not have an established history in clinical use. Most commonly recognized medications like paroxetine hydrochloride, which doctors use to treat depression and anxiety, go through rigorous clinical trials before any health agency gives the green light for use in humans. Their dosing regimens reflect years of research, patient trials, and safety work. N-Benzyl Paroxetine Hydrochloride, though chemically similar, carries a big question mark because of its lack of tested human data.
Chemicals in the pharmaceutical family demand a respectful approach. Paroxetine itself affects serotonin balance in the brain, which means even small deviations in dose can bring on unwanted effects. Headaches, nausea, and insomnia show up quickly. At higher or unstudied doses, one can see serious risks like serotonin syndrome, which is potentially life-threatening. Without the support of trials, no one can say with honesty what a safe or effective dose for N-Benzyl Paroxetine Hydrochloride would look like.
Science leans heavily on evidence, not guesswork. For example, mainstream antidepressants reach the public after comparing thousands of doses in animals, and then in controlled studies with volunteers. Regulators examine the way a compound behaves in the body: how much gets absorbed, how fast it’s cleared, and how it interacts with other drugs. N-Benzyl Paroxetine Hydrochloride hasn't been down that road. What this means, on the ground, is that its use steps outside the guardrails that keep patients safe.
Faced with a novel chemical, it becomes essential to rely on trusted sources. Pharmacists, physicians, and regulatory bodies like the FDA or EMA serve as guides because their recommendations rest on real data, not theory. Anyone coming across N-Benzyl Paroxetine Hydrochloride—sold online or discussed in experimental circles—ought to look for published studies in peer-reviewed journals, not message boards or forums. Claims about recommended doses without scientific backup only add confusion, and sometimes danger.
As someone who’s seen promising compounds turn into trouble when taken without knowledge, I can say the impulse to experiment can end up causing more harm than good. People who need help with depression or anxiety fare better turning to medicines tracked over many years. Relying on established prescribing guidelines and supervision from a qualified clinician keeps risk much lower.
Researchers still find new antidepressants and related compounds that eventually change lives for the better. To reach that point, each chemical, including those like N-Benzyl Paroxetine Hydrochloride, must be put through its paces: animal studies, human trials, scrutiny by drug safety experts. Until then, the best step is education, not experimentation.
For now, the conversation around N-Benzyl Paroxetine Hydrochloride remains one of caution. No established dosage means no safe use outside controlled clinical trials. Those interested in new treatment paths always have the option to look into clinical trial recruitment for promising therapies, where oversight is built-in.
A lot of folks trust that a medication’s impact ends with treating the condition it’s meant to target. Experience has taught me that it rarely stays that simple. Any new drug, especially something as potent as N-Benzyl Paroxetine Hydrochloride, deserves a careful look—one shaped by curiosity, lived moments, and what modern research says.
This compound traces its roots to paroxetine, a well-known antidepressant from the SSRI family. Tinkering with molecules like adding a benzyl group changes how the body interacts with it, how it moves around, and how it might affect the mind. Stepping into new territory always means new risks. I remember when SSRIs first hit the market—folks talked a lot about how they’d finally found relief, but also how nausea, weight gain, or trouble sleeping seemed to tag along.
Among patients, the adjustment period hits hardest. That sense of dizziness, a dry mouth that just won’t quit, stomach troubles, and restless nights—these stories keep popping up in clinics and support groups. More worrying still, an uptick in suicidal thinking during the first few weeks has been get a spotlight in medical warnings. Like a stubborn splinter, these reactions aren’t theoretical; people live them, and they shape trust in new medicines.
Validating experience requires science. Some journals flag that benzylated derivatives, like N-Benzyl Paroxetine Hydrochloride, can cause exaggerated side effects compared to standard paroxetine. Heart palpitations and jumps in blood pressure have been mentioned in a handful of case reports. A cousin drug was tied to withdrawal headaches that lasted for days.
My work in psychiatric communities taught me the subtler toll: sexual dysfunction masks itself quietly but hits quality of life hard. People might not want to talk about it, but it influences relationships and confidence. Others describe blunted emotions—neither happy nor sad—a flatness that weighs them down and sometimes prompts people to abandon treatment.
Doctors weigh side effects against benefits daily. From what I have seen, honest conversation makes a difference. Patients notice when prescribers care enough to share facts and check in regularly. Monitoring goes further than routine lab work. Checking in about mood, sleep, and even daily energy stirs up connections my old mentor always insisted on. Sometimes, it takes adjusting doses or switching medications. You keep an open channel.
People want confidence in what they’re swallowing each day. Improved research transparency matters most—companies should open clinical trial data for review. Pharmacogenetic testing—learning which drugs work best for your personal genes—shows real promise in psychiatry. It’s not a magic bullet, but it cuts down on months of uncomfortable side effects chasing down the right pill.
Support groups play their part. Those shared stories help folks realize they aren’t alone with shaky hands or sleepless nights. Modern medicine has grown by listening to patients, learning from stories, and adapting along the way. Every new compound brings new hope but also new questions. Staying curious, grounded in research, and attentive to those living through side effects will keep that hope well-placed.
If you've ever worked around pharmaceutical chemicals, you know how easy it is to overlook the simple act of storage. It's easy to tuck a bottle on a lab shelf or in a supply room without a second thought. Yet, whenever I've seen mishaps or spoiled samples, sloppy storage practices almost always played a role. N-Benzyl Paroxetine Hydrochloride, a compound often handled in research labs, deserves more care because its chemical behavior is unforgiving if left unchecked.
Moisture stands out as the enemy with many salts, including this one. Any time moisture seeps in, you open the door to degradation. This doesn't just mean losing potency. Breakdown products sometimes turn toxic, or at best, unreliable. In my years as a chemist, I've seen promising research delayed because someone stored critical intermediates near a sink or in a humid warehouse. The safest place? Somewhere dry, away from environmental swings, with humidity well under control. Those desiccators gathering dust in the corner—use them.
Light exposure destabilizes a surprising number of compounds. Even if N-Benzyl Paroxetine Hydrochloride isn’t as photosensitive as some, why leave it up for grabs? I learned early on not to trust overhead lab lights or sunny windows. Opaque, tightly sealed containers, kept in a locked cabinet, give peace of mind. I've watched colleagues lose grant money because a batch broke down from too much exposure. Don’t let a simple detail bring expensive projects to a halt.
Temperature spikes stress molecules. Lab refrigerators get opened constantly, and room temperature isn't always so steady. Someone controls the thermostat, colleagues leave doors wide open, and climate control falters during hot spells. Storage at stable temperature—between 2 to 8°C if possible—keeps compounds true to the specs. Daily checks with a thermometer earn their keep. It doesn’t hurt to log temperature swings either; auditors ask for it. If room storage is the only option, at least shield it from radiators, vents, or direct sunlight.
One bottle looks a lot like another on a cluttered shelf. This is the fastest way to cross-contamination, or worse, chemical accidents. I always label all chemicals with clear, durable tags—compound name, concentration, date of receipt, and hazards. Locked cabinets mean only trained staff handle the stock. Don’t leave samples sitting out after use; I’ve seen spillages and exposures cost people their jobs or even their health. Your workplace gains trust when no one mistakes one powder for another.
In research and drug development, small mistakes snowball. If people on staff don’t know the right conditions—rushing, tired, or new to the job—the company or institution risks regulatory headaches. Documentation matters. Standard Operating Procedures (SOPs) spell out storage directions for N-Benzyl Paroxetine Hydrochloride, and regular refresher training keeps everyone sharp. I’ve witnessed labs held up for weeks because of missing records after an inspection. Smart practices show respect for science and for everyone relying on your work.
Everyone’s seen those stories about people buying weird chemicals online, skipping doctors, taking matters into their own hands. N-Benzyl Paroxetine Hydrochloride pops up on chemical supply lists, research lab invoices, and sometimes, less above-board corners of the internet. Before clicking “Buy Now,” folks need to know this isn’t aspirin. This compound carries some real risks and that changes how people ought to access it.
N-Benzyl Paroxetine Hydrochloride is one of those so-called “research chemicals.” It sits in the same family as paroxetine, a prescription antidepressant better known as Paxil. It’s not just for mood disorders—pharmaceutical labs explore its chemical cousins hoping to discover new treatments for a bunch of conditions. These experiments don’t always say much about safety in people. Since N-Benzyl Paroxetine Hydrochloride isn’t sold as a mainstream drug, there’s no human dosage chart, no user reviews, no doctors tracking side effects in patients.
In most countries, any close relative of paroxetine rides under strict rules. For example, in the United States, paroxetine falls under prescription drug laws. N-Benzyl Paroxetine Hydrochloride isn’t just a scientific curiosity—it could produce strong effects or hidden dangers, some predictable, some not. Pharmacies can’t simply hand it out to anyone with a wallet. Drug regulators designed these rules to stop dangerous self-experimentation, save people from drug interactions they wouldn’t spot, and catch early signs of allergic or toxic reaction.
A lot of people want easy answers and faster solutions. The truth is, the risks are real. Unregulated access puts not just the buyer at risk but families and communities as well. Someone figuring out their own dose with zero medical backup steps into unknown territory. Plenty of tragic stories started from a hunch that “it’ll probably be fine.” Even a science degree doesn’t replace a doctor’s ongoing care.
Without a prescription, buying or possessing substances like N-Benzyl Paroxetine Hydrochloride can break drug laws. Getting caught’s not just about fines. There’s a criminal record, school or job consequences, maybe even a travel ban. Stories from real people often prove more striking than any legal warning. Online forums carry plenty of regret from folks who took risks hoping for a shortcut.
Instead of hunting down sketchy sources, people dealing with depression, anxiety, or chemical curiosity should reach out for actual medical help. Doctors and pharmacists keep up with new research and can recommend tested, effective treatments. Health care professionals don’t just hand out pills—they check for drug reactions, other health conditions, and long-term safety. For chemists and science students, universities and research institutions offer legal, supervised access for legitimate study. These routes create safety nets, not stumbling blocks.
Spreading information, talking openly about the intentions behind these purchases, and encouraging trust between patients and providers matter as much as the legal side. When honest questions don’t get brushed off, fewer people feel forced to experiment in secret. The more we talk about risks, benefits, and responsible choices, the less we gamble with safety. If real treatment’s needed, there’s always a doctor, a nurse, or a pharmacist ready to help.
| Names | |
| Preferred IUPAC name | 1-benzyl-4-(4-fluorophenyl)-6,7-dihydro-1H-pyrido[3,4-b]piperazine hydrochloride |
| Other names |
GSK-372475A N-Benzyl-4-(4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl)-3,4-dihydro-2H-benzopyran-7-ol hydrochloride |
| Pronunciation | /ɛn ˈbɛnzɪl ˌpæroʊˈksɛtiːn haɪˌdrɒklaɪd/ |
| Identifiers | |
| CAS Number | 34785-03-8 |
| Beilstein Reference | Beilstein Reference: 6264525 |
| ChEBI | CHEBI:131346 |
| ChEMBL | CHEMBL2105785 |
| ChemSpider | 24866342 |
| DrugBank | DB11641 |
| ECHA InfoCard | 09dcf9e0-4642-4d71-9bd5-4a3dc2b76395 |
| EC Number | 1140102 |
| Gmelin Reference | 1195196 |
| KEGG | C16139 |
| MeSH | D017962 |
| PubChem CID | 162665191 |
| UNII | F0T79WA6BW |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID40964116 |
| Properties | |
| Chemical formula | C19H21ClFNO2 |
| Molar mass | 398.94 g/mol |
| Appearance | White or off-white solid |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 4.4 |
| Acidity (pKa) | 11.1 |
| Basicity (pKb) | 4.0 |
| Magnetic susceptibility (χ) | -84.8×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.603 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.49 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | N-Benzyl Paroxetine Hydrochloride does not have a widely reported standard molar entropy (S⦵298) value in the literature. |
| Pharmacology | |
| ATC code | N06AB05 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause respiratory irritation |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P261, P264, P271, P272, P280, P302+P352, P305+P351+P338, P362+P364, P501 |
| Flash point | > 98.9 °C |
| LD50 (median dose) | LD50 (median dose): 190 mg/kg (oral, rat) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | REL (Recommended): **2 °C to 8 °C** |
| IDLH (Immediate danger) | IDLH not established |
| Related compounds | |
| Related compounds |
Paroxetine Paroxetine hydrochloride Norparoxetine N-Benzyl Paroxetine Desmethylene Paroxetine |
